LM-24C5 is under clinical development by LaNova Medicines and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LM-24C5’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LM-24C5 overview

LM-24C5 is under development for the treatment of solid tumor, lung cancer, adenocarcinoma of the gastroesophageal junction and colorectal cancer. The drug candidate acts by targeting cells expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and 4-1BB. It is administered through intravenous route.

LaNova Medicines overview

LaNova Medicines (Lanova) is a clinical-stage biotechnology company that discovers and develops antibody-based cancer treatments. The company’s antibody-drug conjugates (ADCs) products pipeline includes LM-302, LM-305, LM-001, LM-002, LM-003, LM-004, LM-005, LM-006, and LM-007. It also develops monoclonal antibodies (mAbs) such as LM-108 and LM-101. Lanova products are used in treating solid tumors, gastrointestinal cancer, multiple myeloma, and hematologic malignancies. The company develops a wide range of tumor-associated antigens (TAA) and immuno-oncology (IO) targets by leveraging its proprietary targeted antibody discovery platform (LX-TAb), next-gen ADC platform (LX-ADC) and immune cell engager platform (LX-TDuo). It works in collaboration with Akesobio, AstraZeneca, Bristol Myers Squibb, Cellular Biomedicine Group (CBMG), and Topalliance Biosciences for clinical development and commercialization. Lanova is headquartered in Shanghai, China.

For a complete picture of LM-24C5’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.